cat feline diabetes medication treatment fda approval cat feline diabetes medication treatment fda approval Boehringer Ingelheim receives FDA approval for SENVELGO®
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Partnership-with-clicktherapeutics Partnership-with-clicktherapeutics Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
biolabs-heidelberg biolabs-heidelberg Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Redefining mental health to enable people to thrive Redefining mental health to enable people to thrive At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Breakthrough Designation granted in US and China Breakthrough Designation granted in US and China SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Boehringer founding sponsor of CKM Health Initiative Boehringer founding sponsor of CKM Health Initiative Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
InSensitive Content: the impact on dermatologists InSensitive Content: the impact on dermatologists Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
InSensitive Content: impact on the GPP patient community InSensitive Content: impact on the GPP patient community Understand why the patient community should be able to post and consume visual content related to generalized pustular psoriasis.
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
EC_approval_nintedanib_ILD_PF EC_approval_nintedanib_ILD_PF European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis